Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

380
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
380
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

554
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
554
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

287
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
287
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

422
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
422
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

2.8K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.8K
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

432
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
432

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of Dupilumab on Health-Related Quality of Life and Respiratory Symptoms in Patients With COPD and Type 2 Inflammation: BOREAS and NOTUS.

Chest·2025
Same author

Histopathology of the small airways: Similarities and differences between ageing and COPD.

Pulmonology·2025
Same author

Improved Annotation of Asthma Gene Variants with Cell Type Deconvolution of Nasal and Lung Expression Quantitative Trait Loci.

American journal of respiratory cell and molecular biology·2025
Same author

Results from a UK consensus about the optimal prescribing of medium strength triple therapy in uncontrolled adult asthma patients in the NHS.

Journal of family medicine and primary care·2025
Same author

A response to therapy for COPD with dupilumab.

The Lancet. Respiratory medicine·2025
Same author

Is Disease Stability an Attainable Chronic Obstructive Pulmonary Disease Treatment Goal?

American journal of respiratory and critical care medicine·2024
Same journal

Psychosocial retrospective follow-up of young adults with congenital adrenal hyperplasia.

European journal of endocrinology·2026
Same journal

Correction to: Steroidogenic factor-1 regulates a core set of target genes to promote malignancy in adrenocortical carcinoma.

European journal of endocrinology·2026
Same journal

Improving post-thyroidectomy care using a PTH and calcium-based algorithm.

European journal of endocrinology·2026
Same journal

Sampling variability and concordance between sequential and simultaneous adrenal venous sampling in primary aldosteronism subtype diagnosis.

European journal of endocrinology·2026
Same journal

Independent Clonal Evolution in Primary Pigmented Nodular Adrenocortical Disease: A Single-Patient Multi-Omics Study.

European journal of endocrinology·2026
Same journal

Twenty years of neurosurgical experience with Cushing's disease: surgical-strategies, endocrine outcomes and remission predictors in 346 patients.

European journal of endocrinology·2026
See all related articles

Related Experiment Video

Updated: Sep 3, 2025

Impact Assessment of Repeated Exposure of Organotypic 3D Bronchial and Nasal Tissue Culture Models to Whole Cigarette Smoke
09:50

Impact Assessment of Repeated Exposure of Organotypic 3D Bronchial and Nasal Tissue Culture Models to Whole Cigarette Smoke

Published on: February 12, 2015

11.3K

Inhaled glucocorticoid-induced metabolome changes in asthma.

Peter Daley-Yates1, Brian Keppler2, Noushin Brealey3

  • 1Clinical Pharmacology and Experimental Medicine, GSK, Uxbridge, UK.

European Journal of Endocrinology
|July 28, 2022
PubMed
Summary
This summary is machine-generated.

Inhaled glucocorticoids (GCs) cause dose-dependent metabolomic changes, primarily at high doses. Fluticasone furoate (FF) showed fewer effects on adrenal steroids at therapeutic doses compared to fluticasone propionate (FP) and budesonide (BUD).

More Related Videos

Intraperitoneal Glucose Tolerance Test, Measurement of Lung Function, and Fixation of the Lung to Study the Impact of Obesity and Impaired Metabolism on Pulmonary Outcomes
08:30

Intraperitoneal Glucose Tolerance Test, Measurement of Lung Function, and Fixation of the Lung to Study the Impact of Obesity and Impaired Metabolism on Pulmonary Outcomes

Published on: March 15, 2018

14.2K
A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice
09:58

A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice

Published on: April 13, 2010

22.6K

Related Experiment Videos

Last Updated: Sep 3, 2025

Impact Assessment of Repeated Exposure of Organotypic 3D Bronchial and Nasal Tissue Culture Models to Whole Cigarette Smoke
09:50

Impact Assessment of Repeated Exposure of Organotypic 3D Bronchial and Nasal Tissue Culture Models to Whole Cigarette Smoke

Published on: February 12, 2015

11.3K
Intraperitoneal Glucose Tolerance Test, Measurement of Lung Function, and Fixation of the Lung to Study the Impact of Obesity and Impaired Metabolism on Pulmonary Outcomes
08:30

Intraperitoneal Glucose Tolerance Test, Measurement of Lung Function, and Fixation of the Lung to Study the Impact of Obesity and Impaired Metabolism on Pulmonary Outcomes

Published on: March 15, 2018

14.2K
A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice
09:58

A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice

Published on: April 13, 2010

22.6K

Area of Science:

  • Metabolomics
  • Pharmacology
  • Endocrinology

Background:

  • Inhaled glucocorticoids (GCs) are widely used for respiratory conditions.
  • Understanding their systemic effects on metabolism is crucial for safety assessment.
  • Previous studies have focused on specific metabolic pathways, but a global metabolome analysis is needed.

Purpose of the Study:

  • To identify dose-related systemic effects of inhaled GCs on the global metabolome.
  • To compare the metabolomic impact of different inhaled GCs at therapeutic and supratherapeutic doses.

Main Methods:

  • Plasma metabolomics/lipidomics analysis from 54 subjects receiving escalating doses of fluticasone furoate (FF), fluticasone propionate (FP), budesonide (BUD), or placebo.
  • Ultrahigh-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) and liquid chromatography-mass spectrometry (LC-MS) were employed for sample analysis.
  • Statistical analysis included repeated measures ANOVA, cross-over model, random forest, and principal component analysis.

Main Results:

  • Few significant metabolomic changes were observed at therapeutic doses compared to placebo.
  • Highest/supratherapeutic doses revealed dose-dependent changes: reduced adrenal steroids (cortisol, cortisone, DHEA-S), increased amino acids and glycolytic intermediates, and decreased fatty acid β-oxidation.
  • Notable differences included lowered dopamine metabolites (BUD) and altered bile acid profiles (BUD/FF), suggesting potential CNS and gut microbiome effects.

Conclusions:

  • Dose-dependent metabolomic changes with inhaled GCs are predominantly seen at supratherapeutic doses, supporting the safety of lower therapeutic doses.
  • At comparable therapeutic doses, FF exhibited the least impact on sensitive markers like adrenal steroids compared to BUD and FP.
  • These findings highlight the importance of dose selection and provide insights into the systemic safety profile of different inhaled GCs.